Regeneron's 63.59% Volume Drop Sends Stock to 282nd in Market Activity Amid Cemdisiran's Promising Trial Results and Competitive Pressures

On August 27, 2025, Regeneron Pharmaceuticals (REGN) traded with a volume of $340 million, a 63.59% decline from the previous day, ranking 282nd in market activity. The stock closed down 0.12%, reflecting muted investor activity despite recent developments in its pipeline.

Regeneron reported positive Phase III trial results for cemdisiran, a subcutaneous siRNA therapy for generalized myasthenia gravis (gMG). The drug met its primary endpoint, showing a statistically significant -2.3 improvement in MG-ADL scores compared to placebo, outperforming AstraZeneca’s Ultomiris and Soliris but trailing UCB’s Rystiggo. Cemdisiran also demonstrated a -4.24 improvement in QMG scores, highlighting its potential as a standalone treatment. The therapy’s once-monthly dosing regimen offers a patient-centric advantage over weekly alternatives, though two deaths occurred during the trial’s extension phase, linked to concomitant immunosuppressive therapies.

The success of cemdisiran validates Regeneron’s $10 million investment to secure global rights to the siRNA technology from Alnylam Pharmaceuticals. However, regulatory approval faces competition from Johnson & Johnson’s recently approved FcRn blocker Imaavy and AstraZeneca’s gefurulimab, which also met Phase III endpoints. While cemdisiran’s dosing frequency may differentiate it, its commercial viability remains contingent on navigating a crowded therapeutic landscape.

Here is some news for you to read: ENGO Eyewear launched ENGO 2, its lightest smart eyewear for sports; Healthy Extracts expanded its product line on Amazon; Chesapeake Utilities’ CEO Jeffry Householder holds significant stock value; the global Smart Shelves market is projected to grow; and Palantir faces a securities lawsuit.